Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…
ADC Combination Therapy: Combining with Targeted Drugs
Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…
ADC Combination Therapy: Combining with Chemotherapy
Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…
Platinum-Resistant Ovarian Cancer to Create New Drugs! FDA Approved ADC Elahere
In November 2022, ImmunoGen announced that the Food and Drug Administration (FDA) has accelerated the approval for Elahere (mirvetuximab soravtansine-gynx): a monotherapy for adult patients with epithelial ovarian, fallopian, and primary peritonealRead More…
ADC Panoramic Overview- Endocytosis of ADC Targeting Antigens
CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…
ADC Panoramic Overview- endocytosis pathway of ADC
Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…
ADC Overview: Bioconjugation Technology Ⅲ
Bioconjugation with engineered unnatural amino acids In addition to the sulfur monoclonal antibody technique, the addition of non-standard amino acids (ncAA) provides another possibility for site-specific conjugation. This technique uses amino acidsRead More…
ADC Overview: Bioconjugation TechnologyⅡ
Site-specific bioconjugation of engineered antibodies Advances in bioorthogonal chemistry and protein engineering have contributed to the production of more uniform ADC. Although there are many attachment methods available for natural McAbs, site-specificRead More…
ADC Overview: Bioconjugation TechnologyⅠ
Chemical modification of specific in situ antibody The natural structure of monoclonal antibodies provides a variety of possibilities for bioconjugation. The chemical-based, specific natural (non-engineered) antibody conjugation has some benefits in thatRead More…
ADC Panoramic Overview-Linker
The linker is not only the molecular part of the covalent connection between the antibody and the small molecular payload but also a key element with design properties in targeted drug therapy.Read More…